vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v22i1.2520vsp-3143Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWГистиоцитоз из клеток Лангерганса у детей: обзор литературыLangerhans Cell Histiocytosis in Children: Literature Reviewhttps://orcid.org/0000-0002-3623-6547БурцевЕ. А.BurtsevEvgeniy A.

Бурцев Евгений Андреевич, врач-гематолог отделения трансплантации костного мозга и гемопоэтических стволовых клеток,

119049, Москва, 4-й Добрынинский пер., д. 1/9

Moscow

burcev.evgeniy@yandex.ruhttps://orcid.org/0000-0002-0694-3996БронинГ. О.BroninGleb O.

Москва

Moscow

Морозовская ДГКБ ДЗМРоссияMorozovskaya Children’s City HospitalRussian Federation2023250220232211322Copyright © Бурцев Е.А., Бронин Г.О., 20232023Бурцев Е.А., Бронин Г.О.Burtsev E.A., Bronin G.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3143

Представлена актуальная информация о развитии и течении гистиоцитоза из клеток Лангерганса у детей. Описаны современные концепции патогенеза заболевания, принципы оценки тяжести и стратификации пациентов в группы риска, а также особенности клинического течения. Обобщены и проанализированы современные подходы к лечению заболевания с использованием таргетной терапии. 

Relevant information on Langerhans cell histiocytosis development and course in children is presented. The current concepts of disease pathogenesis, principles of its severity evaluation, patients stratification into risk groups, as well as of clinical course features are described. Modern approaches to the disease treatment via targeted therapy are summarized and analyzed. 

гистиоцитоз из клеток Лангергансаорганы рискатаргетная терапияLangerhans cell histiocytosisorgans at risktarget therapyReferencesRodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–1331. doi: https://doi.org/10.1182/BLOOD.2019000934Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–1331. doi: https://doi.org/10.1182/BLOOD.2019000934Минков М. Эволюция лечения детей с гистиоцитозом из клеток Лангерганса // Педиатрия. Журнал им. Г.Н. Сперанского. — 2021. — Т. 100. — № 3. — С. 107–120. — doi: https://doi.org/10.24110/0031-403x-2021-100-3-107-120Minkov M. Evolu tion of treatment of children with Langerhans cell histio cytosis. Pediatria. Journal n.a. G.N. Speransky. 2021;100(3):107–120. (In Russ). doi: https://doi.org/10.24110/0031-403x-2021-100-3-107-120Alston RD, Tatevossian RG, McNally RJQ, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007;48(5): 555–560. doi: https://doi.org/10.1002/PBC.20884Alston RD, Tatevossian RG, McNally RJQ, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007;48(5): 555–560. doi: https://doi.org/10.1002/PBC.20884Aricò M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173(5): 663–670. doi: https://doi.org/10.1111/BJH.13955Aricò M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173(5): 663–670. doi: https://doi.org/10.1111/BJH.13955Han D, Li F, Yahya WH, et al. Multisystem Langerhans Cell Histiocytosis in Younger Infants First Presenting in Skin: A Case Series. J Pers Med. 2022;12(7):1024. doi: https://doi.org/10.3390/jpm12071024Han D, Li F, Yahya WH, et al. Multisystem Langerhans Cell Histiocytosis in Younger Infants First Presenting in Skin: A Case Series. J Pers Med. 2022;12(7):1024. doi: https://doi.org/10.3390/jpm12071024Liu H, Stiller CA, Crooks CJ, et al. Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. Br J Haematol. 2022; 199(5):728–738. doi: https://doi.org/10.1111/bjh.18459Liu H, Stiller CA, Crooks CJ, et al. Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. Br J Haematol. 2022; 199(5):728–738. doi: https://doi.org/10.1111/bjh.18459Белова В.Ю., Спичак И.И. Гистиоцитоз из клеток Лангерганса у детей Челябинской области (1995–2018): заболеваемость, клинические формы, программы лечения, выживаемость // Педиатрический вестник Южного Урала. — 2020. — № 1. — 59–65. — doi: https://doi.org/10.34710/chel.2020.61.36.009Belova VYu, Spichak II. Langerhans cell histiocytosis in children of the chelyabinsk region (1995–2018): incidence, clinical forms, treatment programs, survival. Pediatric Bulletin of the Southern Urals. 2020;(1):59–65. (In Russ). doi: https://doi.org/10.34710/chel.2020.61.36.009Ribeiro KB, Degar B, Antoneli CBG, et al. Ethnicity, race, and socioeconomic status influence incidence of langerhans cell histiocytosis. Pediatr Blood Cancer. 2015;62(6):982–987. doi: https://doi.org/10.1002/PBC.25404Ribeiro KB, Degar B, Antoneli CBG, et al. Ethnicity, race, and socioeconomic status influence incidence of langerhans cell histiocytosis. Pediatr Blood Cancer. 2015;62(6):982–987. doi: https://doi.org/10.1002/PBC.25404Lorillon G, Tazi A. How I manage pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26(145):170070. doi: https://doi.org/10.1183/16000617.0070-2017Lorillon G, Tazi A. How I manage pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26(145):170070. doi: https://doi.org/10.1183/16000617.0070-2017Ma J, Laird JH, Chau KW, et al. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Med. 2019;8(1):58–66. doi: https://doi.org/10.1002/CAM4.1844Ma J, Laird JH, Chau KW, et al. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Med. 2019;8(1):58–66. doi: https://doi.org/10.1002/CAM4.1844Bagnasco F, Zimmermann SY, Egeler RM, et al. Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients. Eur J Cancer. 2022;172:138–145. doi: https://doi.org/10.1016/J.EJCA.2022.03.036Bagnasco F, Zimmermann SY, Egeler RM, et al. Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients. Eur J Cancer. 2022;172:138–145. doi: https://doi.org/10.1016/J.EJCA.2022.03.036Feng C, Li Y, Ke H, et al. Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators. Front Oncol. 2021;11:631682. doi: https://doi.org/10.3389/FONC.2021.631682Feng C, Li Y, Ke H, et al. Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators. Front Oncol. 2021;11:631682. doi: https://doi.org/10.3389/FONC.2021.631682Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007;4(8):1374–1384. doi: https://doi.org/10.1371/JOURNAL.PMED.0040253Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007;4(8):1374–1384. doi: https://doi.org/10.1371/JOURNAL.PMED.0040253Morimoto A, Oh Y, Shioda Y, et al. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56(4):451–461. doi: https://doi.org/10.1111/PED.12380Morimoto A, Oh Y, Shioda Y, et al. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56(4):451–461. doi: https://doi.org/10.1111/PED.12380Badalian-Very G, Vergilio J-A, Degar BA, et al. MYELOID NEOPLASIA Brief report Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923. doi: https://doi.org/10.1182/blood-2010-04-279083Badalian-Very G, Vergilio J-A, Degar BA, et al. MYELOID NEOPLASIA Brief report Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923. doi: https://doi.org/10.1182/blood-2010-04-279083Pakneshan S, Salajegheh A, Smith RA, Lam AKY. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–356. doi: https://doi.org/10.1097/PAT.0b013e328360b61dPakneshan S, Salajegheh A, Smith RA, Lam AKY. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–356. doi: https://doi.org/10.1097/PAT.0B013doi: E328360B61DYaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329–341. doi: https://doi.org/10.1158/2159-8290.CD-18-1321Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329–341. doi: https://doi.org/10.1158/2159-8290.CD-18-1321Thevakumaran N, Lavoie H, Critton DA, et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol. 2015;22(1):37–43. doi: https://doi.org/10.1038/NSMB.2924Thevakumaran N, Lavoie H, Critton DA, et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol. 2015;22(1):37–43. doi: https://doi.org/10.1038/NSMB.2924Brown NA, Furtado LV, Betz BL, et al. Brief Report MYELOID NEOPLASIA High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10): 1655–1658. doi: https://doi.org/10.1182/blood-2014-05Brown NA, Furtado LV, Betz BL, et al. Brief Report MYELOID NEOPLASIA High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10): 1655–1658. doi: https://doi.org/10.1182/blood-2014-05Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activa ting ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20): 3152–3155. doi: https://doi.org/10.1182/BLOOD-2013-06-511139Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activa ting ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20): 3152–3155. doi: https://doi.org/10.1182/BLOOD-2013-06-511139Ali S, Bailey M, Stephens P, et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017;2(3):e89473. doi: https://doi.org/10.1172/jci.insight.89473Ali S, Bailey M, Stephens P, et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017;2(3):e89473. doi: https://doi.org/10.1172/jci.insight.89473Rollins BJ. Genomic Alterations in Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):839–851. doi: https://doi.org/10.1016/J.HOC.2015.06.004Rollins BJ. Genomic Alterations in Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):839–851. doi: https://doi.org/10.1016/J.HOC.2015.06.004Gulati N, Allen CE. Langerhans cell histiocytosis: Version 2021. Hematol Oncol. 2021;39(Suppl 1):15–23. doi: https://doi.org/10.1002/HON.2857Gulati N, Allen CE. Langerhans cell histiocytosis: Version 2021. Hematol Oncol. 2021;39(Suppl 1):15–23. doi: https://doi.org/10.1002/HON.2857Berres M-L, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2014;169(1):3–13. doi: https://doi.org/10.1111/bjh.13247Berres M-L, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2014;169(1):3–13. doi: https://doi.org/10.1111/bjh.13247Berres ML, Lim KPH, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–683. doi: https://doi.org/10.1084/JEM.20130977Berres ML, Lim KPH, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–683. doi: https://doi.org/10.1084/JEM.20130977Mass E, Jacome-Galarza CE, Blank T, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549(7672):389–393. doi: https://doi.org/10.1038/nature23672Mass E, Jacome-Galarza CE, Blank T, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549(7672):389–393. doi: https://doi.org/10.1038/nature23672McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018;124(12): 2607–2620. doi: https://doi.org/10.1002/CNCR.31348McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018;124(12): 2607–2620. doi: https://doi.org/10.1002/CNCR.31348Haupt R, Minkov M, Astigarraga I, et al. Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years. Pediatr Blood Cancer. 2013;60(2):175–184. doi: https://doi.org/10.1002/pbc.24367Haupt R, Minkov M, Astigarraga I, et al. Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years. Pediatr Blood Cancer. 2013;60(2):175–184. doi: https://doi.org/10.1002/pbc.24367Jezierska M, Stefanowicz J, Romanowicz G, et al. Langerhans cell histiocytosis in children — A disease with many faces. Recent advances in pathogenesis, diagnosticexaminations and treatment. Postepy Dermatol Alergol. 2018;35(1):6–17. doi: https://doi.org/10.5114/pdia.2017.67095Jezierska M, Stefanowicz J, Romanowicz G, et al. Langerhans cell histiocytosis in children — A disease with many faces. Recent advances in pathogenesis, diagnosticexaminations and treatment. Postepy Dermatol Alergol. 2018;35(1):6–17. doi: https://doi.org/10.5114/pdia.2017.67095Khung S, Budzik JF, Amzallag-Bellenger E, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013; 4(5):569–579. doi: https://doi.org/10.1007/S13244-013-0271-7Khung S, Budzik JF, Amzallag-Bellenger E, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013; 4(5):569–579. doi: https://doi.org/10.1007/S13244-013-0271-7Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans’ cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005;35(2):103–115. doi: https://doi.org/10.1007/S00247-004-1262-0Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans’ cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005;35(2):103–115. doi: https://doi.org/10.1007/S00247-004-1262-0Abdelaal AHK, Sedky M, Gohar S, et al. Skeletal involvement in children with Langerhans cell histiocytosis: healing, complications, and functional outcome. SICOT-J. 2020;6:28. doi: https://doi.org/10.1051/SICOTJ/2020024Abdelaal AHK, Sedky M, Gohar S, et al. Skeletal involvement in children with Langerhans cell histiocytosis: healing, complications, and functional outcome. SICOT-J. 2020;6:28. doi: https://doi.org/10.1051/SICOTJ/2020024Allen CE, Flores R, Rauch R, et al. Neurodegenerative Central Nervous System Langerhans Cell Histiocytosis and Coincident Hydrocephalus: Treated with Vincristine/Cytosine Arabinoside. Pediatr Blood Cancer. 2010;54(3):416–423. doi: https://doi.org/10.1002/PBC.22326Allen CE, Flores R, Rauch R, et al. Neurodegenerative Central Nervous System Langerhans Cell Histiocytosis and Coincident Hydrocephalus: Treated with Vincristine/Cytosine Arabinoside. Pediatr Blood Cancer. 2010;54(3):416–423. doi: https://doi.org/10.1002/PBC.22326Luz J, Zweifel D, Hüllner M, et al. Oral manifestation of Langerhans cell histiocytosis: a case report. BMC Oral Health. 2018;18(1): 106. doi: https://doi.org/10.1186/S12903-018-0568-5Luz J, Zweifel D, Hüllner M, et al. Oral manifestation of Langerhans cell histiocytosis: a case report. BMC Oral Health. 2018;18(1): 106. doi: https://doi.org/10.1186/S12903-018-0568-5Lakatos K, Sterlich K, Pötschger U, et al. Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings. J Pediatr. 2021;230:174–181.e1. doi: https://doi.org/10.1016/J.JPEDS.2020.10.056Lakatos K, Sterlich K, Pötschger U, et al. Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings. J Pediatr. 2021;230:174–181.e1. doi: https://doi.org/10.1016/J.JPEDS.2020.10.056Parikh SN, Desai VR, Gupta A, Anton CG. Langerhans Cell Histiocytosis of the Clavicle in a 13-Year-Old Boy. Case Rep Orthop. 2014;2014:510287. doi: https://doi.org/10.1155/2014/510287Parikh SN, Desai VR, Gupta A, Anton CG. Langerhans Cell Histiocytosis of the Clavicle in a 13-Year-Old Boy. Case Rep Orthop. 2014;2014:510287. doi: https://doi.org/10.1155/2014/510287Song YS, Lee IS, Yi JH, et al. Radiologic findings of adult pelvis and appendicular skeletal Langerhans cell histiocytosis in nine patients. Skeletal Radiol. 2011;40(11):1421–1426. doi: https://doi.org/10.1007/S00256-010-1078-YSong YS, Lee IS, Yi JH, et al. Radiologic findings of adult pelvis and appendicular skeletal Langerhans cell histiocytosis in nine patients. Skeletal Radiol. 2011;40(11):1421–1426. doi: https://doi.org/10.1007/S00256-010-1078-Y 38. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–S89. doi: https://doi.org/10.1016/J.BBMT.2009.11.014Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–S89. doi: https://doi.org/10.1016/J.BBMT.2009.11.014Morren MA, Vanden Broecke K, Vangeebergen L, et al. Diverse Cutaneous Presentations of Langerhans Cell Histiocytosis in Children: A Retrospective Cohort Study. Pediatr Blood Cancer. 2016;63(3):486–492. doi: https://doi.org/10.1002/PBC.25834Morren MA, Vanden Broecke K, Vangeebergen L, et al. Diverse Cutaneous Presentations of Langerhans Cell Histiocytosis in Children: A Retrospective Cohort Study. Pediatr Blood Cancer. 2016;63(3):486–492. doi: https://doi.org/10.1002/PBC.25834Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014;165(5):990–996. doi: https://doi.org/10.1016/J.JPEDS.2014.07.063Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014;165(5):990–996. doi: https://doi.org/10.1016/J.JPEDS.2014.07.063Battistella M, Fraitag S, Teillac DH, et al. Neonatal and early infantile cutaneous langerhans cell histiocytosis: comparison of self-regressive and non-self-regressive forms. Arch Dermatol. 2010;146(2):149–156. doi: https://doi.org/10.1001/ARCHDERMATOL.2009.360Battistella M, Fraitag S, Teillac DH, et al. Neonatal and early infantile cutaneous langerhans cell histiocytosis: comparison of self-regressive and non-self-regressive forms. Arch Dermatol. 2010;146(2):149–156. doi: https://doi.org/10.1001/ARCHDERMATOL.2009.360Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006;46(1):66–71. doi: https://doi.org/10.1002/PBC.20479Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006;46(1):66–71. doi: https://doi.org/10.1002/PBC.20479Chander R, Jaykar K, Varghese B, et al. Pulmonary disease with striking nail involvement in a child. Pediatr Dermatol. 2008;25(6): 633–634. doi: https://doi.org/10.1111/J.1525-1470.2008.00788.XChander R, Jaykar K, Varghese B, et al. Pulmonary disease with striking nail involvement in a child. Pediatr Dermatol. 2008;25(6): 633–634. doi: https://doi.org/10.1111/J.1525-1470.2008.00788.XYadav SP, Kharya G, Mohan N, et al. Langerhans cell histiocytosis with digestive tract involvement. Pediatr Blood Cancer. 2010;55(4):748–753. doi: https://doi.org/10.1002/PBC.22663Yadav SP, Kharya G, Mohan N, et al. Langerhans cell histiocytosis with digestive tract involvement. Pediatr Blood Cancer. 2010;55(4):748–753. doi: https://doi.org/10.1002/PBC.22663Singhi AD, Montgomery EA. Gastrointestinal tract langerhans cell histiocytosis: A clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–310. doi: https://doi.org/10.1097/PAS.0B013E31820654E4Singhi AD, Montgomery EA. Gastrointestinal tract langerhans cell histiocytosis: A clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–310. doi: https://doi.org/10.1097/PAS.0B013E31820654E4Barclay M, Devaney R, Bhatt JM. Paediatric pulmonary Langerhans cell histiocytosis. Breathe (Sheff). 2020;16(2):200003. doi: https://doi.org/10.1183/20734735.0003-2020Barclay M, Devaney R, Bhatt JM. Paediatric pulmonary Langerhans cell histiocytosis. Breathe (Sheff). 2020;16(2):200003. doi: https://doi.org/10.1183/20734735.0003-2020Evseev DA, Kalinina II, Uskova NG, et al. The use of preventive pleurodesis in patient with Langerhans-cell histiocytosis with lung involvement: the case report and the review. Pediatric Hematology/Oncology and Immunopathology. 2018;17(3):74–80. (In Russ). doi: https://doi.org/10.24287/1726-1708-2018-17-3-74-80Евсеев Д.А., Калинина И.И., Ускова Н.Г. и др. Применение превентивного плевродеза у пациента с гистиоцитозом из клеток Лангерганса с поражением легких // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. — 2018. — Т. 17. — № 3. — С. 74–80. — doi: https://doi.org/10.24287/1726-1708-2018-17-3-74-80Ronceray L, Pötschger U, Janka G, et al. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome. J Pediatr. 2012;161(1):129–133.e1–3. doi: https://doi.org/10.1016/J.JPEDS.2011.12.035Ronceray L, Pötschger U, Janka G, et al. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome. J Pediatr. 2012;161(1):129–133.e1–3. doi: https://doi.org/10.1016/J.JPEDS.2011.12.035Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26(5):351–356. doi: https://doi.org/10.1016/J.EJIM.2015.04.001Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26(5):351–356. doi: https://doi.org/10.1016/J.EJIM.2015.04.001Bano S, Chaudhary V, Narula MK, et al. Pulmonary Langerhans cell histiocytosis in children: a spectrum of radiologic findings. Eur J Radiol. 2014;83(1):47–56. doi: https://doi.org/10.1016/J.EJRAD.2013.04.044Bano S, Chaudhary V, Narula MK, et al. Pulmonary Langerhans cell histiocytosis in children: a spectrum of radiologic findings. Eur J Radiol. 2014;83(1):47–56. doi: https://doi.org/10.1016/J.EJRAD.2013.04.044Abba ME, Żegleń S, Łącka M, et al. Lung Transplant in a Patient With Multifocal Langerhans Cell Histiocytosis After Chemotherapy With Cladribine: A Case Report. Transplant Proc. 2022;54(4): 1177–1179. doi: https://doi.org/10.1016/J.TRANSPROCEED.2022.02.037Abba ME, Żegleń S, Łącka M, et al. Lung Transplant in a Patient With Multifocal Langerhans Cell Histiocytosis After Chemotherapy With Cladribine: A Case Report. Transplant Proc. 2022;54(4): 1177–1179. doi: https://doi.org/10.1016/J.TRANSPROCEED.2022.02.037Nezelof C, Frileux‐Herbet F, Cronier‐Sachot J. Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases. Cancer. 1979;44(5):1824–1838. doi: https://doi.org/10.1002/1097-0142(197911)44:53.0.co;2-jNezelof C, Frileux‐Herbet F, Cronier‐Sachot J. Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases. Cancer. 1979;44(5):1824–1838. doi: https://doi.org/10.1002/1097-0142(197911)44:53.0.co;2-jBraier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol. 1999;16(5):377–385. doi: https://doi.org/10.1080/088800199276921Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol. 1999;16(5):377–385. doi: https://doi.org/10.1080/088800199276921Minkov M, Pötschger U, Grois N, et al. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;49(5):694–698. doi: https://doi.org/10.1002/PBC.21227Minkov M, Pötschger U, Grois N, et al. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;49(5):694–698. doi: https://doi.org/10.1002/PBC.21227Donadieu J, Chalard F, Jeziorski E. Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13(9):1309–1322. doi: https://doi.org/10.1517/14656566.2012.688028Donadieu J, Chalard F, Jeziorski E. Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13(9):1309–1322. doi: https://doi.org/10.1517/14656566.2012.688028Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocy tosis. Med Pediatr Oncol. 2002;38(3):178–182. doi: https://doi.org/10.1002/MPO.1306Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocy tosis. Med Pediatr Oncol. 2002;38(3):178–182. doi: https://doi.org/10.1002/MPO.1306Yi X, Han T, Zai H, et al. Liver involvement of Langerhans’ cell histiocytosis in children. Int J Clin Exp Med. 2015;8(5):7098. 58. Grana N. Langerhans cell histiocytosis. Cancer Control. 2014; 21(4):328–334. doi: https://doi.org/10.1177/107327481402100409Yi X, Han T, Zai H, et al. Liver involvement of Langerhans’ cell histiocytosis in children. Int J Clin Exp Med. 2015;8(5):7098.Hong L, Sun G, Peng L, et al. Solated Langerhans cell histiocytosis of the spleen: A case report. Medicine (Baltimore). 2018;97(38): e12378. doi: https://doi.org/10.1097/MD.0000000000012378Grana N. Langerhans cell histiocytosis. Cancer Control. 2014; 21(4):328–334. doi: https://doi.org/10.1177/107327481402100409Edelweiss M, Medeiros LJ, Suster S, Moran CA. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol. 2007; 38(10):1463–1469. doi: https://doi.org/10.1016/J.HUMPATH. 2007.03.015Hong L, Sun G, Peng L, et al. Solated Langerhans cell histiocytosis of the spleen: A case report. Medicine (Baltimore). 2018;97(38): e12378. doi: https://doi.org/10.1097/MD.0000000000012378Yeh EA, Greenberg J, Abla O, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018;65(1). doi: https://doi.org/10.1002/PBC.26784Edelweiss M, Medeiros LJ, Suster S, Moran CA. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol. 2007; 38(10):1463–1469. doi: https://doi.org/10.1016/J.HUMPATH.2007.03.015Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–881. e1. doi: https://doi.org/10.1016/J.JPEDS.2010.03.001Yeh EA, Greenberg J, Abla O, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018;65(1). doi: https://doi.org/10.1002/PBC.26784Crois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–233. doi: https://doi.org/10.1002/PBC.20425Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–881. e1. doi: https://doi.org/10.1016/J.JPEDS.2010.03.001Nanduri VR, Bareille P, Pritchard J, Stanhope R. Growth and endocrine disorders in multisystem Langerhans’ cell histiocytosis. Clin Endocrinol (Oxf). 2000;53(4):509–515. doi: https://doi.org/10.1046/J.1365-2265.2000.01125.XCrois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–233. doi: https://doi.org/10.1002/PBC.20425Chaudhary V, Bano S, Aggarwal R, et al. Neuroimaging of Langerhans cell histiocytosis: a radiological review. Jpn J Radiol. 2013;31(12):786–796. doi: https://doi.org/10.1007/S11604-013-0254-0Nanduri VR, Bareille P, Pritchard J, Stanhope R. Growth and endocrine disorders in multisystem Langerhans’ cell histiocytosis. Clin Endocrinol (Oxf). 2000;53(4):509–515. doi: https://doi.org/10.1046/J.1365-2265.2000.01125.XGabbay LB, Leite C da C, Andriola RS, et al. Histiocytosis: a review focusing on neuroimaging findings. Arq Neuropsiquiatr. 2014;72(7):548–558. doi: https://doi.org/10.1590/0004-282X20140063Chaudhary V, Bano S, Aggarwal R, et al. Neuroimaging of Langerhans cell histiocytosis: a radiological review. Jpn J Radiol. 2013;31(12):786–796. doi: https://doi.org/10.1007/S11604-013-0254-0Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138(5):728–734. doi: https://doi.org/10.1067/mpd.2001.111331Gabbay LB, Leite C da C, Andriola RS, et al. Histiocytosis: a review focusing on neuroimaging findings. Arq Neuropsiquiatr. 2014;72(7):548–558. doi: https://doi.org/10.1590/0004-282X20140063Gadner H, Grois N, Pötschger U, et al. Improved outcome in multi system Langerhans cell histiocytosis is associated with therapy in ten sification. Blood. 2008;111(5):2556–2562. doi: https://doi.org/10.1182/blood-2007-08-106211Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138(5):728–734. doi: https://doi.org/10.1067/mpd.2001.111331Grois N, Prayer D, Prosch H, Lassmann H. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005;128 (Pt 4):829–838. doi: https://doi.org/10.1093/BRAIN/AWH403Gadner H, Grois N, Pötschger U, et al. Improved outcome in multi system Langerhans cell histiocytosis is associated with therapy in ten sification. Blood. 2008;111(5):2556–2562. doi: https://doi.org/10.1182/blood-2007-08-106211Gadner H, Heitger A, Ritter J, et al. Langerhans cell histiocytosis in childhood--results of the DAL-HX 83 study. Klin Padiatr. 1987;199(3):173–182. doi: https://doi.org/10.1055/s-2008-1026785Grois N, Prayer D, Prosch H, Lassmann H. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005;128 (Pt 4):829–838. doi: https://doi.org/10.1093/BRAIN/AWH403Ceci A, De Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X ’83 study. Med Pediatr Oncol. 1993;21(4):259–264. doi: https://doi.org/10.1002/MPO.2950210405Gadner H, Heitger A, Ritter J, et al. Langerhans cell histiocytosis in childhood--results of the DAL-HX 83 study. Klin Padiatr. 1987;199(3):173–182. doi: https://doi.org/10.1055/s-2008-1026785Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–5014. doi: https://doi.org/10.1182/blood-2012-09Ceci A, De Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X ’83 study. Med Pediatr Oncol. 1993;21(4):259–264. doi: https://doi.org/10.1002/MPO.2950210405Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011;13(2):75–86. doi: https://doi.org/10.2165/11538540-000000000-00000Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–5014. doi: https://doi.org/10.1182/blood-2012-09Héritier S, Jehanne M, Leverger G, et al Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis JAMA Oncol. 2015;1(6):836–838. doi: https://doi.org/10.1001/jamaoncol.2015.0736Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011;13(2):75–86. doi: https://doi.org/10.2165/11538540-000000000-00000Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31): 2857–2865. doi: https://doi.org/10.1200/JCO.19.00456Héritier S, Jehanne M, Leverger G, et al Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis JAMA Oncol. 2015;1(6):836–838. doi: https://doi.org/10.1001/jamaoncol.2015.0736Evseev D, Kalinina I, Raykina E, et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cellfree circulating DNA. Int J Hematol. 2021;114(6):725–734. doi: https://doi.org/10.1007/s12185-021-03205-8Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31): 2857–2865. doi: https://doi.org/10.1200/JCO.19.00456Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms HHS Public Access. Nature. 2019;567:521–4. doi: https://doi.org/10.1038/s41586-019-1012-yEvseev D, Kalinina I, Raykina E, et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cellfree circulating DNA. Int J Hematol. 2021;114(6):725–734. doi: https://doi.org/10.1007/s12185-021-03205-8Burtsev EA, Bronin GO. MEK-inhibitors in treatment of Langerhans cell histiocytosis. Russian Journal of Pediatric Hematology and Oncology. 2022;9(3):42–47. (In Russ). doi: https://doi.org/10.21682/2311-1267-2022-9-3-42-47Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms HHS Public Access. Nature. 2019;567:521–4. doi: https://doi.org/10.1038/s41586-019-1012-yAwada G, Seremet T, Fostier K, et al. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Adv. 2018;2(16):2156–2158. doi: https://doi.org/10.1182/BLOODADVANCES.2018021782Бурцев Е.А. Бронин Г.О. MEK-ингибиторы в терапии гистиоцитоза из клеток Лангерганса // Российский журнал детской гематологии и онкологии. — 2022. — Т. 9. — № 3. — С. 42–47. — doi: https://doi.org/10.21682/2311-1267-2022-9-3-42-47Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008;50(1):72–79. doi: https://doi.org/10.1002/PBC.21225Awada G, Seremet T, Fostier K, et al. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Adv. 2018;2(16):2156–2158. doi: https://doi.org/10.1182/BLOODADVANCES.2018021782Abla O, Weitzman S, Minkov M, et al. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated? Pediatr Blood Cancer. 2009;52(5):555–556. doi: https://doi.org/10.1002/PBC.21924Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008;50(1):72–79. doi: https://doi.org/10.1002/PBC.21225Abla O, Palmert MR. Reversal of LCH-related diabetes insipidus and reappearance of posterior pituitary bright spot with low-dose chemotherapy. Pediatr Blood Cancer. 2012;59(1):201–202. doi: https://doi.org/10.1002/PBC.24061Abla O, Weitzman S, Minkov M, et al. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated? Pediatr Blood Cancer. 2009;52(5):555–556. doi: https://doi.org/10.1002/PBC.21924Imashuku S, Okazaki N, Nakayama M, et al. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer. 2008;50(2):308–311. doi: https://doi.org/10.1002/PBC.21259Abla O, Palmert MR. Reversal of LCH-related diabetes insipidus and reappearance of posterior pituitary bright spot with low-dose chemotherapy. Pediatr Blood Cancer. 2012;59(1):201–202. doi: https://doi.org/10.1002/PBC.24061Gavhed D, Laurencikas E, Åkefeldt SO, Henter JI. Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis. Acta Paediatr. 2011;100(7):e36–e39. doi: https://doi.org/10.1111/J.1651-2227.2010.02125.XImashuku S, Okazaki N, Nakayama M, et al. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer. 2008;50(2):308–311. doi: https://doi.org/10.1002/PBC.21259Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in “degenerative-like” neuro-langerhans cell histiocytosis: a pros pective pilot study. Pediatr Blood Cancer. 2004;43(1):55–58. doi: https://doi.org/10.1002/PBC.20040Gavhed D, Laurencikas E, Åkefeldt SO, Henter JI. Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis. Acta Paediatr. 2011;100(7):e36–e39. doi: https://doi.org/10.1111/J.1651-2227.2010.02125.XEuskirchen P, Haroche J, Emile JF, et al. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflammation. 2015;2(2):e78. doi: https://doi.org/10.1212/NXI.0000000000000078Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in “degenerative-like” neuro-langerhans cell histiocytosis: a pros pective pilot study. Pediatr Blood Cancer. 2004;43(1):55–58. doi: https://doi.org/10.1002/PBC.20040Sveijer M, Von Bahr Greenwood T, Jädersten M, et al. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. Br J Haematol. 2022;198(4): 721–728. doi: https://doi.org/10.1111/bjh.18247Euskirchen P, Haroche J, Emile JF, et al. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflammation. 2015;2(2):e78. doi: https://doi.org/10.1212/NXI.0000000000000078Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. Expert Opin Pharmacother. 2018;19(3):233–42. doi: https://doi.org/10.1080/14656566.2018.1429405Sveijer M, Von Bahr Greenwood T, Jädersten M, et al. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. Br J Haematol. 2022;198(4): 721–728. doi: https://doi.org/10.1111/bjh.18247Volkova EN, Bronin GO, Vysotskaya TA, et al. Rezul’taty retrospektivnogo monotsentrovogo issledovaniya gistiotsitoza iz kletok langergansa u detei. Pediatria. Journal n.a. G.N. Speransky. 2009;87(4):33–40. (In Russ).Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. Expert Opin Pharmacother. 2018;19(3):233–42. doi: https://doi.org/10.1080/14656566.2018.1429405Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society — Late Effects Study Group. Pediatr Blood Cancer. 2004;42(5):438–444. doi: https://doi.org/10.1002/PBC.20021Волкова Е.Н., Бронин Г.О., Высоцкая Т.А. и др. Результаты ретроспективного моноцентрового исследования гистиоцитоза из клеток лангерганса у детей // Педиатрия. Журнал им. Г.Н. Сперанского. — 2009. — Т. 87. — № 4. — С. 33–40.Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14(7): 2073–2082. doi: https://doi.org/10.1200/JCO.1996.14.7.2073Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society — Late Effects Study Group. Pediatr Blood Cancer. 2004;42(5):438–444. doi: https://doi.org/10.1002/PBC.20021Gurieva OD, Valiev TT, Pavlovskaya AI. Histiocytic neoplasms: modern aspects of pathogenesis, classification, diagnosis and treatment. Oncohematology. 2022;17(1):10–25. (In Russ). doi: https://doi.org/10.17650/1818Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14(7): 2073–2082. doi: https://doi.org/10.1200/JCO.1996.14.7.2073Chow TW, Leung WK, Cheng FWT, et al. Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child. 2017;102(9):830– 835. doi: https://doi.org/10.1136/ARCHDISCHILD-2016-312185Гурьева О.Д., Валиев Т.Т., Павловская А.И. Гистиоцитарные опухоли: современные аспекты патогенеза, классификации, диагностики и лечения // Онкогематология. — 2022. — Т. 17. — № 1. — С. 10–25. — doi: https://doi.org/10.17650/1818Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887–898. doi: https://doi.org/10.1111/BJH.14140Chow TW, Leung WK, Cheng FWT, et al. Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child. 2017;102(9):830– 835. doi: https://doi.org/10.1136/ARCHDISCHILD-2016-312185Di Iorgi N, Allegri AEM, Napoli F, et al. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014;99(4):1264–1272. doi: https://doi.org/10.1210/JC.2013-3724Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887–898. doi: https://doi.org/10.1111/BJH.14140Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans’ cell histiocytosis. Int J Pediatr Otorhinolaryngol. 1998;46(1-2):109–115. doi: https://doi.org/10.1016/S0165-5876(98)00116-5Di Iorgi N, Allegri AEM, Napoli F, et al. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014;99(4):1264–1272. doi: https://doi.org/10.1210/JC.2013-3724Di Iorgi N, Allegri AEM, Napoli F, et al. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014;99(4):1264–1272. doi: https://doi.org/10.1210/JC.2013-3724Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans’ cell histiocytosis. Int J Pediatr Otorhinolaryngol. 1998;46(1-2):109–115. doi: https://doi.org/10.1016/S0165-5876(98)00116-5Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans’ cell histiocytosis. Int J Pediatr Otorhinolaryngol. 1998;46(1-2):109–115. doi: https://doi.org/10.1016/S0165-5876(98)00116-5

The authors declare that there are no conflicts of interest present.